Scopolamine Induced Model

Scopolamine is a non-selective muscarinic receptor antagonist that impairs spatial learning and memory abilities by blocking cholinergic signaling as well as some possible indirect effects. It is one of the commonly used drugs in chemical-induced Alzheimer's disease model. For example, rat dementia is usually induced by intraperitoneal injection for two weeks (1mg/kg).

Scopolamine induced model Figure. 1. Pharmacological changes of scopolamine-induced AD model

Creative Bioarray has many years of experience in the field of Alzheimer's disease and provides pharmacodynamic services for customers to help them assess the efficacy of compounds and study the associated pathological mechanisms of Alzheimer's disease through scopolamine induced model.

Our Capabilities

  • We can provide comprehensive behavioral and cognitive testing on AD model and the drug screening.
  • We can utilize LTP (long-term potentiation) assay to evaluate your preclinical drug candidates against the synaptic impairments in animals.
  • We can evaluate anti-oxidative stress in the hippocampus of animals treated with drug candidates.
  • We can evaluate various biomarkers through WB, IHC, ELISA, sequencing, etc.

Assays available

  • Learning and memory deficits tests
  • Synaptic impairment
  • Oxidative stress
  • Neuroinflammation
  • Phosphorylated tau
  • Glycogen synthase kinase-3 beta (GSK3β)
  • Neurofilament Light Chain levels
  • Neuronal loss
  • β-AP level
  • Plaque load
  • β-sheet load
  • pE(3)-Aβ load
  • Enzyme activity related to cholinergic system
  • NMDA receptor function and excitotoxicity
  • Mitochondrial dysfunction
  • Brain slice staining and synaptic electrophysiology
  • Blood brain barrier homeostasis
  • Cerebral vascular angiopathy (CAA)

With years of experience in AD research field, Creative Bioarray understands how to help design the studies to obtain rapid and clear answers to meet our customers’ need. Our in vivo animal models are capable of providing a rapid screening of the neuroprotective potential agents for the treatment of AD.

Study examples

Scopolamine induced modelFigure. 2. 7,8-Dihydroxyflflavone (7,8-DHF) attenuated scopolamine-induced learning and memory defificits. (A) Latency of the rats to find the platform during the training section. Latency (B) and crossing time (C) of the rats on the 7th day. (D) Swimming speed of all groups. (*) p < 0.05, (**) p < 0.01 versus the control (Con) group, (#) p < 0.05, (##) p < 0.01versus the scopolamine (Sco) group. S + D, Sco + 7.8-DHF.

Scopolamine induced model Figure. 3. 7,8-Dihydroxyflflavone (7,8-DHF) reversed scopolamine (Sco)-induced synaptic impairments. (A) Normalized population spike (PS) amplitude. (B) Normalized excitatory postsynaptic potential (EPSP) slope. S + D, Sco + 7.8-DHF; Con, control; HFS, high-frequency stimulation.

Quotation and ordering

Contact us if you have any questions. Our customer service representatives are available 24hr a day.

Reference

  1. Veronese N et al. Association Between Short Physical Performance Battery and Falls in Older People: The Progetto Veneto Anziani Study[J]. Rejuvenation Research, 2014, 17(3):276-284.

For research use only. Not for any other purpose.